Generalized Anxiety Disorder Gad Affects Multiple Areas - amazonia.fiocruz.br

Generalized Anxiety Disorder Gad Affects Multiple Areas Video

Latest news

The purpose of this study is to investigate the effects of agomelatine on anxious symptoms and functional impairment in a pooled dataset from randomized placebo-controlled trials for generalized anxiety disorder GAD. Meta-analysis using a random effect model was used to assess differences between groups. Remission and response rates for the HAM-A and SDS were calculated, and analyses were repeated in participants with more severe anxiety symptoms. In total, patients on agomelatine; on placebo were included in the analyses. Compared to placebo, the agomelatine group had a significant reduction in HAM-A total score at week 12 between group difference: 6.

Associated Data

Significant effects were also found for symptom response on the HAM-A Compared to placebo, there was a significant difference in favour of the agomelatine group at week 12 on the SDS total score 5. Genetalized effects were also found for functional response on the SDS All findings for anxious symptoms and functional impairment were confirmed in the subset of more severely anxious patients.

Agomelatine was well tolerated by patients. This meta-analysis confirms that agomelatine reduces anxiety symptoms and improves the global functioning of GAD patients.

This article is published with digital features, including a summary slide, to facilitate understanding of the article. Generalized anxiety disorder GAD is a chronic condition characterized by excessive worry, together with psychic and somatic symptoms of anxiety. GAD is the most common anxiety disorder in primary care practice [ 123 ], and is often associated with both comorbidity including major depression and other anxiety disorders and morbidity including psychosocial impairment and economic costs [ 1 ].

While a number of different medication classes have demonstrated efficacy in the management of GAD and cognitive behavioural therapy remains an important treatment option [ 4 ], there is considerable interest in alternative therapies [ 567 ].

Treatment Programs are OPEN During Covid-19

Additionally, there are significant adverse events associated with the commonly used benzodiazepines, including withdrawal [ 8 ]. In contrast to antidepressants, which inhibit monoamine uptake, benzodiazepines that act on the GABAergic system, Disordre buspirone which is also used in GAD management and which behaves as a 5-HT1A partial agonist [ 6 ], agomelatine possesses a quite different mechanism of action.

Multuple Furthermore, with regards to GAD symptoms, antagonism at 5-HT2C receptors may underlie the apparent anxiolytic properties of agomelatine, while melatonin agonism may improve sleep and circadian rhythmicity [ 912 ]. Two short-term, double-blind studies and one relapse prevention trial have evaluated the efficacy of agomelatine in the treatment of GAD [ 13141516 ].]